IN2014DN06220A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN06220A IN2014DN06220A IN6220DEN2014A IN2014DN06220A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A IN 6220DEN2014 A IN6220DEN2014 A IN 6220DEN2014A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A
- Authority
- IN
- India
- Prior art keywords
- exons
- dystrophin gene
- human dystrophin
- oligomer
- drug
- Prior art date
Links
- 108700024394 Exon Proteins 0.000 abstract 2
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011288040 | 2011-12-28 | ||
| JP2012043092 | 2012-02-29 | ||
| PCT/JP2012/084295 WO2013100190A1 (ja) | 2011-12-28 | 2012-12-27 | アンチセンス核酸 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06220A true IN2014DN06220A (OSRAM) | 2015-10-23 |
Family
ID=48697653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6220DEN2014 IN2014DN06220A (OSRAM) | 2011-12-28 | 2012-12-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9512424B2 (OSRAM) |
| EP (2) | EP3594347A1 (OSRAM) |
| JP (6) | JP6141770B2 (OSRAM) |
| KR (2) | KR102240139B1 (OSRAM) |
| CN (10) | CN110055243B (OSRAM) |
| AU (2) | AU2012360702C1 (OSRAM) |
| CA (2) | CA3132111A1 (OSRAM) |
| ES (1) | ES2748868T3 (OSRAM) |
| IN (1) | IN2014DN06220A (OSRAM) |
| RU (3) | RU2619184C2 (OSRAM) |
| TW (1) | TWI606059B (OSRAM) |
| WO (1) | WO2013100190A1 (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| HUE028662T2 (en) | 2007-10-26 | 2016-12-28 | Academisch Ziekenhuis Leiden | Preparations and methods for controlling muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| TR201902952T4 (tr) | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| WO2011057350A1 (en) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| IN2014DN06220A (OSRAM) * | 2011-12-28 | 2015-10-23 | Nippon Shinyaku Co Ltd | |
| CN111893117B (zh) | 2012-01-27 | 2024-06-04 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| MX373959B (es) | 2013-03-15 | 2020-07-13 | Sarepta Therapeutics Inc | Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd). |
| EP3514234A1 (en) * | 2014-03-12 | 2019-07-24 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
| ES2930274T3 (es) * | 2014-05-19 | 2022-12-09 | Knc Laboratories Co Ltd | Fármaco de ácido nucleico para inducir la omisión de variantes exónicas del gen de CD44 y aumentar la expresión de ARNm de CD44 de tipo normal |
| UA121117C2 (uk) | 2014-06-17 | 2020-04-10 | Ніппон Шин'Яку Ко., Лтд. | Антисенсова нуклеїнова кислота |
| CN106795186B (zh) | 2014-10-14 | 2021-03-02 | 味之素株式会社 | 吗啉代寡核苷酸的制备方法 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| RU2724554C2 (ru) * | 2015-09-15 | 2020-06-23 | Ниппон Синяку Ко., Лтд. | Антисмысловая нуклеиновая кислота |
| JP7511326B2 (ja) | 2015-10-09 | 2024-07-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物およびその方法 |
| BR112018007066A2 (pt) | 2015-10-09 | 2018-10-23 | Sarepta Therapeutics Inc | composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados |
| EP3464305B1 (en) * | 2016-05-24 | 2024-08-21 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
| CN109311920B (zh) * | 2016-05-24 | 2021-11-09 | 萨勒普塔医疗公司 | 制备磷酸二酰胺吗啉代寡聚物的方法 |
| JP2019525742A (ja) | 2016-06-30 | 2019-09-12 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
| CA3046220A1 (en) * | 2016-12-08 | 2018-06-14 | The Board Of Regents Of The University Of Texas System | Dmd reporter models containing humanized duschene muscular dystrophy mutations |
| KR20240006023A (ko) * | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| EP3554553B1 (en) | 2016-12-19 | 2022-07-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CA3047010A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| US20210145852A1 (en) | 2017-09-28 | 2021-05-20 | Sarepta Therapeutics, Inc. | Combination Therapies for Treating Muscular Dystrophy |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EA202191601A1 (ru) * | 2018-12-13 | 2022-01-19 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| AU2018454784A1 (en) * | 2018-12-25 | 2021-08-05 | National Center Of Neurology And Psychiatry | Method for inducing muscular cells using cells in spot urine |
| AU2020263487A1 (en) | 2019-04-25 | 2021-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| MX2022007491A (es) * | 2019-12-19 | 2022-08-15 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido que permite la omision de exones. |
| CN118109469A (zh) | 2019-12-26 | 2024-05-31 | 日本新药株式会社 | 诱导外显子50的跳读的反义核酸 |
| IL307937A (en) | 2021-04-30 | 2023-12-01 | Sarepta Therapeutics Inc | Treatment methods for muscular dystrophy |
| WO2022239863A1 (ja) | 2021-05-13 | 2022-11-17 | 国立大学法人千葉大学 | アンチセンスオリゴマー |
| TW202307208A (zh) | 2021-06-23 | 2023-02-16 | 日商日本新藥股份有限公司 | 反義寡聚物之組合 |
| CN118201606A (zh) | 2021-07-08 | 2024-06-14 | 日本新药株式会社 | 肾毒性减轻剂 |
| CN118475355A (zh) | 2021-07-08 | 2024-08-09 | 日本新药株式会社 | 肾毒性减轻剂 |
| TW202317147A (zh) | 2021-07-08 | 2023-05-01 | 日商日本新藥股份有限公司 | 析出抑制劑 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20240318176A1 (en) * | 2021-07-09 | 2024-09-26 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| MX2024000489A (es) | 2021-07-09 | 2024-04-09 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y formulaciones para el tratamiento de las distrofinopatías. |
| WO2023026994A1 (ja) | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート |
| US20250066396A1 (en) | 2021-12-27 | 2025-02-27 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| JP2025079347A (ja) * | 2022-03-11 | 2025-05-22 | 日本新薬株式会社 | キャリアペプチドが連結された核酸 |
| US20250195667A1 (en) | 2022-03-17 | 2025-06-19 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| US12071621B2 (en) * | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991009033A1 (en) | 1989-12-20 | 1991-06-27 | Anti-Gene Development Group | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体，デバイス及び医薬組成物 |
| FI951138L (fi) * | 1993-07-13 | 1995-04-13 | Rhone Poulenc Rorer Sa | Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa |
| US6727355B2 (en) * | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
| EP1191097A1 (en) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| CA2942791C (en) | 2002-11-25 | 2019-08-20 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| USRE47769E1 (en) * | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| EP1811024A1 (en) | 2004-10-05 | 2007-07-25 | Nippon Shinyaku Co., Ltd. | Oligo double-stranded rna and medicinal composition |
| KR20080031164A (ko) * | 2005-04-22 | 2008-04-08 | 아카데미슈 지켄후이스 라이덴 | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 |
| WO2006129594A1 (ja) | 2005-05-30 | 2006-12-07 | Nippon Shinyaku Co., Ltd. | 核酸含有複合体製剤の製造方法 |
| US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| US8466255B2 (en) | 2007-02-05 | 2013-06-18 | Nippon Shinyaku Co., Ltd. | Polyethylene glycol derivative |
| HUE028662T2 (en) | 2007-10-26 | 2016-12-28 | Academisch Ziekenhuis Leiden | Preparations and methods for controlling muscle disorders |
| HRP20140646T1 (hr) | 2007-11-15 | 2014-09-26 | Sarepta Therapeutics, Inc. | Postupak sinteze morfolino oligomera |
| EP2119783A1 (en) * | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| TR201902952T4 (tr) * | 2008-10-24 | 2019-03-21 | Sarepta Therapeutics Inc | Dmd için ekson atlama bileşimleri. |
| PT2344637E (pt) | 2008-10-27 | 2015-03-23 | Academisch Ziekenhuis Leiden | Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne |
| JP2012524540A (ja) * | 2009-04-24 | 2012-10-18 | プロセンサ テクノロジーズ ビー．ブイ． | Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド |
| US20120270930A1 (en) * | 2009-10-29 | 2012-10-25 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Methods and compositions for dysferlin exon-skipping |
| WO2011057350A1 (en) | 2009-11-12 | 2011-05-19 | The University Of Western Australia | Antisense molecules and methods for treating pathologies |
| CA2799501C (en) * | 2010-05-28 | 2022-02-15 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| JP5593949B2 (ja) | 2010-08-17 | 2014-09-24 | 横河電機株式会社 | プログラマブルロジックコントローラ |
| IN2014DN06220A (OSRAM) * | 2011-12-28 | 2015-10-23 | Nippon Shinyaku Co Ltd |
-
2012
- 2012-12-27 IN IN6220DEN2014 patent/IN2014DN06220A/en unknown
- 2012-12-27 CN CN201910167486.0A patent/CN110055243B/zh active Active
- 2012-12-27 CN CN201810389950.6A patent/CN108611349A/zh active Pending
- 2012-12-27 US US14/368,307 patent/US9512424B2/en active Active
- 2012-12-27 CN CN202311738073.6A patent/CN117721110A/zh active Pending
- 2012-12-27 CN CN201810389811.3A patent/CN108486116A/zh active Pending
- 2012-12-27 EP EP19182708.8A patent/EP3594347A1/en active Pending
- 2012-12-27 KR KR1020207001044A patent/KR102240139B1/ko active Active
- 2012-12-27 AU AU2012360702A patent/AU2012360702C1/en active Active
- 2012-12-27 CN CN201910167466.3A patent/CN110079525A/zh active Pending
- 2012-12-27 CN CN201280064590.3A patent/CN104024414A/zh not_active Withdrawn
- 2012-12-27 CA CA3132111A patent/CA3132111A1/en active Pending
- 2012-12-27 WO PCT/JP2012/084295 patent/WO2013100190A1/ja not_active Ceased
- 2012-12-27 CA CA2861247A patent/CA2861247C/en active Active
- 2012-12-27 RU RU2014130600A patent/RU2619184C2/ru active
- 2012-12-27 RU RU2017114509A patent/RU2651468C1/ru active
- 2012-12-27 CN CN201910167665.4A patent/CN110055244A/zh not_active Withdrawn
- 2012-12-27 CN CN201711192063.1A patent/CN107881175B/zh active Active
- 2012-12-27 KR KR1020147018749A patent/KR102071729B1/ko active Active
- 2012-12-27 ES ES12861221T patent/ES2748868T3/es active Active
- 2012-12-27 CN CN202410462539.2A patent/CN118207212A/zh active Pending
- 2012-12-27 EP EP12861221.5A patent/EP2799548B1/en active Active
- 2012-12-27 JP JP2013551878A patent/JP6141770B2/ja active Active
- 2012-12-27 CN CN201810389742.6A patent/CN108588073A/zh active Pending
- 2012-12-28 TW TW101150922A patent/TWI606059B/zh active
-
2016
- 2016-10-31 US US15/339,069 patent/US9890381B2/en active Active
-
2017
- 2017-05-08 JP JP2017092674A patent/JP6734222B2/ja active Active
-
2018
- 2018-01-12 US US15/870,308 patent/US10781448B2/en active Active
- 2018-03-21 RU RU2018109906A patent/RU2681470C1/ru active
- 2018-09-14 AU AU2018229530A patent/AU2018229530B2/en active Active
-
2020
- 2020-03-09 JP JP2020039457A patent/JP7038365B2/ja active Active
- 2020-08-21 US US16/999,695 patent/US20210222169A1/en not_active Abandoned
-
2021
- 2021-12-20 JP JP2021206326A patent/JP2022058379A/ja not_active Withdrawn
-
2023
- 2023-12-26 JP JP2023218763A patent/JP2024038103A/ja active Pending
-
2024
- 2024-11-19 US US18/951,819 patent/US20250188459A1/en active Pending
-
2025
- 2025-09-02 JP JP2025145028A patent/JP2025176110A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06220A (OSRAM) | ||
| PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
| EP2828275A4 (en) | SYNTHESIS OF 3-O-FUCOSYLLACTOSE TYPE TRISACCHARIDE AND ITS INTERMEDIATES | |
| PH12016501761A1 (en) | Antisense nucleic acids | |
| SI3378862T1 (sl) | Dihidropirimidinoizokuinolini in farmacevtski sestavki le-teh za zdravljenje multiple skleroze | |
| IL225769A0 (en) | Piperidine-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| IT1401855B1 (it) | Apparecchiatura per il trattamento di un prodotto. | |
| IL235349A0 (en) | Therapeutic use of Chardonnay grape products | |
| ZA201307956B (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
| HUE036248T2 (hu) | Aminoglükozidok és alkalmazásaik genetikai rendellenességek kezelésére | |
| EP2971156A4 (en) | Genes and gene signatures for diagnosis and treatment of melanoma | |
| IN2015DN01524A (OSRAM) | ||
| IL225406B (en) | Therapeutic applications of smad7 | |
| EP3052654A4 (en) | Identification of structurally similar small molecules that enhance therapeutic exon skipping | |
| EP2798450A4 (en) | TRIGGERING THE DISPLAY OF ELEMENTS | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| EP2661434A4 (en) | NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER | |
| ZA201306420B (en) | Regulated gene expression systems and constructs thereof | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
| IL237781A0 (en) | A novel phenylacetamide compound, and a drug containing it | |
| IN2015DN02647A (OSRAM) | ||
| IT1403250B1 (it) | Macroapparato per la produzione e il trattamento di gas | |
| GB201008916D0 (en) | Means for inhibiting the expression of gene associated with retinoid IFN-beta induced mortality-19 (grim-19) |